NEFAs characteristically are elevated in obese NIDDM patients in both the basal state and after insulin. This elevation might aggravate glycemic control both by decreasing peripheral glucose disposal (glucose-fatty acid cycle), and by increasing HGO. Thus, lowering plasma NEFA levels might improve carbohydrate metabolism. We therefore measured HGO and fuel use (by indirect calorimetry) both in the basal state and during the last 30 min of a hyperinsulinemic clamp (0.025U · kg−1 · h−1) in 8 obese NIDDM patients (BMI 34.8 ±1.0 kg/m2) after complete overnight suppression of plasma NEFA levels with acipimox, a new nicotinic acid analogue. After acipimox, mean basal plasma NEFA and glycerol levels were lower than control values (0.11 ± 0.02 vs. 0.65 ±0.04 mM, P < 0.001; and 16 ± 3 vs. 68 ± 7 μM, P = 0.004, respectively) and were accompanied by a fall in lipid oxidation (acipimox vs. placebo: 16.1 ±1.2 vs. 38.8 ± 2.4 mg · m−2 · min−1; P < 0.001) and a rise in glucose oxidation (91.1 ± 6.2 vs. 54.1 ± 9.0 mg · m−2 · min−1; P = 0.002). Basal HGO and fasting plasma glucose levels were lower (94.1 ± 9.2 vs. 118.5 ± 9.5 mg · m−2 · min−1 P = 0.01; and 8.3 ± 1.2 vs. 9.8 ± 1.2 mM; P < 0.001), respectively. Serum insulin levels were similar during the clamps (44.2 ± 4.9 vs. 48.2 ± 5.7 μU/L; NS), but despite this, HGO was suppressed more after acipimox (18.2 ± 7.6 vs. 49.7 ± 12.9 mg · m−2 · min−1; P < 0.01), and the metabolic clearance rate for glucose was higher (101.98 ± 19.34 vs. 75.43 ± 9.94 ml · m−2 · min−1; P < 0.05). In conclusion, prolonged overnight suppression of lipolysis and lipid oxidation in obese NIDDM lowers fasting blood glucose and HGO and increases peripheral and hepatic sensitivity to insulin in obese NIDDM patients.
Skip Nav Destination
Article navigation
Original Articles|
November 01 1992
Metabolic Effects of Suppression of Nonesterified Fatty Acid Levels With Acipimox in Obese NIDDM Subjects
G R Fulcher;
G R Fulcher
Department of Medicine, The Medical School, Framlington Place, University of Newcastle Upon Tyne
Newcastle-Upon-Tyne, United Kingdom
Search for other works by this author on:
M Walker;
M Walker
Department of Medicine, The Medical School, Framlington Place, University of Newcastle Upon Tyne
Newcastle-Upon-Tyne, United Kingdom
Search for other works by this author on:
C Catalano;
C Catalano
Department of Medicine, The Medical School, Framlington Place, University of Newcastle Upon Tyne
Newcastle-Upon-Tyne, United Kingdom
Search for other works by this author on:
L Agius;
L Agius
Department of Medicine, The Medical School, Framlington Place, University of Newcastle Upon Tyne
Newcastle-Upon-Tyne, United Kingdom
Search for other works by this author on:
K G M M Alberti
K G M M Alberti
Department of Medicine, The Medical School, Framlington Place, University of Newcastle Upon Tyne
Newcastle-Upon-Tyne, United Kingdom
Search for other works by this author on:
Address correspondence and reprint requests to Dr. G. R. Fulcher, Department of Endocrinology, The Royal North Shore Hospital, Pacific Highway, St Leonards, 2065, Sydney, Australia.
Diabetes 1992;41(11):1400–1408
Article history
Received:
September 05 1991
Revision Received:
March 03 1992
Accepted:
March 03 1992
Citation
G R Fulcher, M Walker, C Catalano, L Agius, K G M M Alberti; Metabolic Effects of Suppression of Nonesterified Fatty Acid Levels With Acipimox in Obese NIDDM Subjects. Diabetes 1 November 1992; 41 (11): 1400–1408. https://doi.org/10.2337/diab.41.11.1400
Download citation file:
20
Views